Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136598 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BDPP4RORCNFKB1 | |
| SCHEMBL2853339 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BDPP4RORCNFKB1 | |
| SCHEMBL22484264 | 0.89 | DPP4 (0.36) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL4108255 | 0.87 | DPP4 (0.35) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL4108252 | 0.87 | DPP4 (0.35) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL29738304 | 0.83 | SMN1; SMN2 (0.38) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL28674890 | 0.83 | SMN1; SMN2 (0.38) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL2859258 | 0.83 | SMN1; SMN2 (0.38) | MTNR1AMTNR1BDPP4RORCSMN1; SMN2 | |
| SCHEMBL13780954 | 0.79 | DPP4 (0.36) | DPP4RORCSMN1; SMN2 | |
| SCHEMBL22484266 | 0.78 | MTNR1A (0.37) | MTNR1AMTNR1BRORCSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2381772-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | MTNR1A 1829/4885MTNR1B 1158/4885DPP4 1/4885 |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | NR4A3, GRIA3, NR2C2 | MTNR1A 317/4885MTNR1B 712/4885DPP4 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.